Journal of
Microbiology and Antimicrobials

  • Abbreviation: J. Microbiol. Antimicrob.
  • Language: English
  • ISSN: 2141-2308
  • DOI: 10.5897/JMA
  • Start Year: 2009
  • Published Articles: 157

Full Length Research Paper

AmpC beta-lactamase production among Pseudomonas aeruginosa and Proteus mirabilis isolates at the Komfo Anokye Teaching Hospital, Kumasi, Ghana

Feglo, P.*
  • Feglo, P.*
  • Department of Clinical Microbiology, School of Medical Sciences, College of Health Sciences, KNUST, Kumasi, Ghana.
  • Google Scholar
Opoku, S
  • Opoku, S
  • Department of Clinical Microbiology, School of Medical Sciences, College of Health Sciences, KNUST, Kumasi, Ghana.
  • Google Scholar


  •  Accepted: 16 January 2014
  •  Published: 31 January 2014

Abstract

Extended spectrum β-lactamases (ESBLs) are frequently reported in Ghana, but AmpC bacteria reports are scanty. This study determines the prevalence of AmpC Pseudomonas aeruginosa and Proteus mirabilis clinical isolates at the Komfo Anokye Teaching Hospital (KATH), Kumasi, where ESBL and AmpC are not routinely tested. Non-duplicate 245 isolates comprising 187 (76.3%) P. aeruginosa and 58 (23.7%) P. mirabilis were tested for AmpC and ESBL production using the modified three-dimensional test method and the double disc synergy test (DDST) methods, respectively. The proportion of the 245 isolates producing AmpC β-lactamase was 93 (38.0%) and 79 (32.2%) produced ESBL. AmpC producers confirmed 49 (52.7%) as inducible and 44 (47.3%) non-inducible AmpC producers. P. aeruginosa and P. mirabilis that produced AmpC were 84 (44.9%) and 9 (15.5%), respectively. ESBL production was 41 (21.9%) in P. aeruginosa and 38 (65.6%) in P. mirabilis. Co-producers of AmpC together with ESBL were 7.3%. Both enzyme were detectable in 13 (7.0%) of P. aeruginosa and 5 (8.6%) of P. mirabilis. AmpC and ESBL are detectable in high proportions among P. aeruginosa and P. mirabilis isolates at KATH and the Kumasi community. This emphasizes the need to start testing for both enzymes to guide therapeutics.

Key words: AmpC beta-lactamase, extended spectrum beta-lactamase, inducible AmpC beta-lactamase, non-inducible beta-lactamase.